Treatment of advanced non-small cell lung cancer

被引：27

作者：

De Petris, L

Crinò, L

Scagliotti, GV

Gridelli, C

Galetta, D

Metro, G

Novello, S

Maione, P

Colucci, G

de Marinis, F

机构：

[1] S Camillo Forlanini Hosp, Dept Lung Dis, Pneumooncol Unit 5, I-00149 Rome, Italy

[2] Policlin Hosp, Div Med Oncol, Perugia, Italy

[3] Univ Turin, S Luigi Hosp, Thorac Oncol Unit, Orbassano, Italy

[4] SG Moscati Hosp, Med Oncol Unit, Avellino, Italy

[5] Inst Oncol, Med & Expt Oncol Unit, Bari, Italy

[6] Bellaria Hosp, Div Med Oncol, Bologna, Italy

[7] FoRO Oncol Res Fdn, Rome, Italy

来源：

ANNALS OF ONCOLOGY | 2006年 / 17卷

关键词：

non-small cell lung cancer; advanced disease; platinum-based chemotherapy; docetaxel; pemetrexed; EGFR inhibitors; PS; 2; patients; pharmacogenomics;

D O I：

10.1093/annonc/mdj919

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the last decade the treatment of advanced-metastatic non-small cell lung cancer has substantially improved. If in the early 90s there was still concern about the real efficacy of chemotherapy over best supportive care alone in the advanced setting, constant developments in clinical research have demonstrated the survival advantage of active anti-cancer drugs not only in the first-line setting, but, lately, even in patients with recurrent disease after failure of two previous chemotherapy lines. With the premises of high throughput technologies, translational research is aiming to characterize patients and tumors on a molecular basis. With pharmacogenomics it would then be possible to accurately predict patient outcome and tailor the treatment strategy according to the geno-phenotype of single patients.

引用

页码：36 / 41

页数：6

共 53 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2] Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome [J].

Anderson, H. ;

Hopwood, P. ;

Stephens, R. J. ;

Thatcher, N. ;

Cottier, B. ;

Nicholson, M. ;

Milroy, R. ;

Maughan, T. S. ;

Falk, S. J. ;

Bond, M. G. ;

Burt, P. A. ;

Connolly, C. K. ;

McIllmurray, M. B. ;

Carmichael, J. .

BRITISH JOURNAL OF CANCER, 2000, 83 (04) :447-453

[3] Prognostic factors in non-small cell lung cancer - A decade of progress [J].

Brundage, MD ;

Davies, D ;

Mackillop, WJ .

CHEST, 2002, 122 (03) :1037-1057

[4] Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer:: A randomized phase III study of the Italian lung cancer project [J].

Crinò, L ;

Scagliotti, GV ;

Ricci, S ;

De Marinis, F ;

Rinaldi, M ;

Gridelli, C ;

Ceribelli, A ;

Bianco, R ;

Marangolo, M ;

Di Costanzo, F ;

Sassi, M ;

Barni, S ;

Ravaioli, A ;

Adamo, V ;

Portalone, L ;

Cruciani, G ;

Masotti, A ;

Ferrara, G ;

Gozzelino, F ;

Tonato, M .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3522-3530

[5] Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A meta-analysis of the published literature [J].

D'Addario, G ;

Pintilie, M ;

Leighl, NB ;

Feld, R ;

Cerny, T ;

Shepherd, FA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2926-2936

[6] ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC) [J].

Felip, E ;

Stahel, RA ;

Pavlidis, N .

ANNALS OF ONCOLOGY, 2005, 16 :28-29

[7] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[8] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[9] Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial [J].

Georgoulias, V ;

Papadakis, E ;

Alexopoulos, A ;

Tsiafaki, X ;

Rapti, A ;

Veslemes, M ;

Palamidas, P ;

Vlachonikolis, I .

LANCET, 2001, 357 (9267) :1478-1484

[10] Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) [J].

Gervais, R ;

Ducolone, A ;

Breton, JL ;

Braun, D ;

Lebeau, B ;

Vaylet, F ;

Debieuvre, D ;

Pujol, JL ;

Tredaniel, J ;

Clouet, P ;

Quoix, E .

ANNALS OF ONCOLOGY, 2005, 16 (01) :90-96

← 1 2 3 4 5 6 →